Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment
复制标题
DOI：
10.1007/s00702-004-0123-1
复制
发表时间：
2004-08-01
影响因子：
3.3
通讯作者：
Nappi, G
中科院分区：
文献类型：
--
作者：
Blandini, F;Cosentino, M;Nappi, G
在这项研究中，我们调查是否可以检测到，外周，帕金森病（PD）患者的细胞凋亡和氧化应激的调节机制的变化。为此，我们测量了caspase-3活性，Bcl-2浓度，外周苯二氮卓类受体（PBR）的表达和Cu/Zn超氧化物歧化酶（SOD）浓度在淋巴细胞中的未经治疗的PD患者，患者仅与L-多巴或与L-多巴和多巴胺激动剂和健康志愿者。Caspase-3活性在所有PD患者组中均显著增加。L-Dopa和多巴胺激动剂治疗的患者显示Bcl-2的最低值，加上PBRs的最高密度，而在L-Dopa单药治疗组中发现Cu/Zn SOD水平升高。我们还发现，在PD患者中，Bcl-2水平与疾病的持续时间和严重程度之间存在明显的负相关性。我们的研究结果指出，PD患者的细胞凋亡的调节机制的变化-可观察到的中枢神经系统外-这似乎是调制的多巴胺能药物的药理学治疗。
In this study, we investigated whether changes in the regulatory mechanisms of apoptosis and oxidative stress may be detected, peripherally, in patients with Parkinson's disease (PD). For this purpose, we measured caspase-3 activity, Bcl-2 concentrations, peripheral benzodiazepine receptor (PBR) expression and Cu/Zn superoxide dismutase (SOD) concentrations in lymphocytes of untreated PD patients, patients treated only with L-Dopa or with L-Dopa and dopamine agonists and healthy volunteers. Caspase-3 activity was significantly increased in all PD patient groups. Patients treated with L-Dopa and dopamine agonists showed the lowest values of Bcl-2, coupled with the highest density of PBRs, while increased levels of Cu/Zn SOD were found in the group under monotherapy with L-Dopa. We also found, in PD patients, clear, negative correlations between Bcl-2 levels and both duration and severity of the disease. Our findings point to the existence of changes in the regulatory mechanisms of apoptosis in PD patients - observable outside the central nervous system - which seem to be modulated by the pharmacological treatment with dopaminergic agents.